Recent PublicationsView all

  • [Show abstract] [Hide abstract]
    ABSTRACT: Oncofoetal antigens are present during foetal development with generally limited expression in the adult but are upregulated in cancer. These molecules can sometimes be used to diagnose or follow treatment of tumours or as a target for different immunotherapies. The 5T4 oncofoetal glycoprotein was identified by searching for shared surface molecules of human trophoblast and cancer cells with the rationale that they may function to allow survival of the foetus as a semi-allograft in the mother or a tumour in its host, potentially influencing growth, invasion or altered immune surveillance of the host. 5T4 tumour selective expression has stimulated the development of 5T4 vaccine, 5T4 antibody targeted-superantigen and 5T4 antibody-drug therapies through preclinical and into clinical studies. It is now apparent that 5T4 expression is a marker of the use (or not) of several cellular pathways relevant to tumour growth and spread. Thus 5T4 expression is mechanistically associated with the directional movement of cells through epithelial mesenchymal transition, facilitation of CXCL12/CXCR4 chemotaxis, blocking of canonical Wnt/beta-catenin while favouring non-canonical pathway signalling. These processes are highly regulated in development and in normal adult tissues but can contribute to the spread of cancer cells. Understanding the differential impact of these pathways marked by 5T4 can potentially improve existing, or aid development of novel cancer treatment strategies.
    No preview · Article · Jul 2014 · Seminars in Cancer Biology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Receptor tyrosine kinase pathways are potential therapeutic targets in gastric adenocarcinoma patients. We evaluated HER2 and cMet protein expression, and FGFR2 gene amplification to assess their prognostic significance, and downstream mediators pS6 and pERK for their potential utility as pharmacodynamic biomarkers in patients with gastric adenocarcinoma. Tissue microarrays were constructed from resection samples of 184 patients who underwent surgery for gastric/gastro-oesophageal junction adenocarcinoma. Tissue cores were obtained from the tumour body (TB), luminal surface (LS) and invasive edge (IE), and immunohistochemical and fluorescence in situ hybridisation (FGFR2) analysis was performed. FGFR2 amplification was identified in 2 % of cases and associated with worse survival (P = 0.005). HER2 overexpression was observed in 10 % of cases and associated with increased survival (P = 0.041). cMet overexpression was observed in 4 % of cases and associated with worse survival (P < 0.001). On multivariate analysis, only cMet retained significance (P = 0.006). pS6 and pERK expression were observed in 73 % and 30 % of tumours, respectively, with no association with survival. HER2 (P = 0.004) and pERK (P = 0.001) expression differed between tumour regions with HER2 expression increased in the LS compared with the TB and IE. These findings confirm subpopulations in gastric adenocarcinoma with poor outcome that may benefit from specific therapeutic strategies. However, we found heterogeneous HER2, pS6 and pERK overexpression, which presents challenges for their use as predictive biomarkers in gastric biopsies. The potential downstream pharmacodynamic markers pS6 and pERK were expressed across tumour regions, providing evidence that resections and biopsies would yield comparative results in clinical trials.
    No preview · Article · Dec 2013 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In chronic myeloid leukaemia, (CML), cells from different stages of maturation may have differential expression of BCR-ABL at both mRNA and protein level. However, the significance of such differential expression to clinical disease behaviour is unknown. Using the CML-derived, BCR-ABL expressing cell line, K562, distinct plastic-adherent (K562/Adh) and non-adherent (K562/NonAdh) sub-populations were established then analysed both as single cells and as bulk cell populations. BCR-ABL mRNA was up-regulated in K562/Adh compared to K562/NonAdh cells in both single cell and bulk population analyses (p<0.0001). Similarly, phosphorylation of BCR protein was up-regulated in K562/Adh, compared to K562/NonAdh cells (63.42% vs 23.1%, p=0.007), and these two K562 sub-populations were found to express significantly different miRNA species. Furthermore, treatment with the BCR-ABL tyrosine kinase inhibitor, imatinib, reduced cell viability more rapidly in K562/NonAdh compared to K562/Adh cells (p<0.005) both at single and bulk cell levels. This discovery of an adherent sub-population of K562 cells with increased BCR-ABL mRNA, increased phosphorylated BCR protein expression, differential miRNA expression, and increased imatinib resistance, suggests a similar sub-population of cells may also mediate clinical resistance to imatinib during treatment of CML patients.
    Full-text · Article · Nov 2013 · Experimental hematology
Information provided on this web page is aggregated encyclopedic and bibliographical information relating to the named institution. Information provided is not approved by the institution itself. The institution’s logo (and/or other graphical identification, such as a coat of arms) is used only to identify the institution in a nominal way. Under certain jurisdictions it may be property of the institution.